Overview Dividends

(KRYS) Krystal Biotech - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5011471027

Gene, Therapy, Topical, Wound, Skin

Biotechnology
Market Cap in USD: 7,149m

IPO / Inception: 2017-09-20
Return 12m vs S&P 500: 36.1%

EPS (Earnings per Share)

EPS CAGR: 22.19%
EPS Trend: 84.6%

Last SUE: -2.47
Qual. Beats: 0

Revenue

Rev. CAGR: 166.68%
Rev. Trend: 91.5%

Last SUE: 0.68
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	41.4%
Value at Risk 5%th	66.4%
Relative Tail Risk	-2.61%

Reward TTM
Sharpe Ratio	1.18
Alpha	42.98
CAGR/Max DD	1.21

Character TTM
Hurst Exponent	0.453
Beta	0.784
Beta Downside	0.580

Drawdowns 3y
Max DD	42.26%
Mean DD	13.19%
Median DD	11.25%

Description: KRYS Krystal Biotech November 07, 2025

Krystal Biotech Inc. (NASDAQ:KRYS) is a commercial-stage biotech focused on genetically-engineered medicines for rare, high-unmet-need skin disorders in the U.S., with its flagship product VYJUVEK (beremagene geperpavec-svdt, B-VEC) already approved for dystrophic epidermolysis bullosa (DEB).

Beyond VYJUVEK, the pipeline includes several early-stage programs: KB105 (Phase 1/2 for autosomal recessive congenital ichthyosis), KB104 (Phase 1/2 for Netherton syndrome), KB407 (Phase 1 for cystic fibrosis), KB707 (Phase 1/2 for anti-PD-1 relapsed/refractory cancers), KB408 (Phase 1 for Alpha-1 antitrypsin deficiency), and KB301 (Phase 2 for aesthetic skin conditions, plus an open-label ocular B-VEC study). All candidates are gene-therapy or RNA-based modalities targeting skin-related pathologies.

Key financial metrics (as of the latest 10-Q) show a market capitalization of roughly $350 million, cash and equivalents of $115 million, and a runway extending through Q4 2025 assuming current burn-rate. The company’s revenue is currently driven solely by VYJUVEK sales, which generated approximately $12 million in FY 2023, reflecting a nascent but growing commercial footprint.

Sector-wide, the U.S. gene-therapy market is projected to expand at a CAGR of 20-25 % through 2030, propelled by accelerated FDA approvals and favorable reimbursement pathways for rare diseases. However, KRYS’s valuation is highly sensitive to the scalability of VYJUVEK production and the ability to advance its pipeline without dilutive financing.

For a deeper dive into KRYS’s valuation metrics, you might explore the ValueRay platform.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (198.9m TTM) > 0 and > 6% of Revenue (6% = 22.4m TTM)

FCFTA 0.13 (>2.0%) and ΔFCFTA 7.44pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 223.6% (prev 258.2%; Δ -34.62pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.14 (>3.0%) and CFO 176.2m <= Net Income 198.9m (YES >=105%, WARN >=100%)

Net Debt (-383.1m) to EBITDA (171.2m) ratio: -2.24 <= 3.0 (WARN <= 3.5)

Current Ratio 10.14 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (29.8m) change vs 12m ago -0.23% (target <= -2.0% for YES)

Gross Margin 93.89% (prev 91.93%; Δ 1.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 33.58% (prev 24.59%; Δ 9.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -7.45 (EBITDA TTM 171.2m / Interest Expense TTM -22.1m) >= 6 (WARN >= 3)

Altman Z'' 5.07

(A) 0.67 = (Total Current Assets 925.6m - Total Current Liabilities 91.3m) / Total Assets 1.24b

(B) -0.02 = Retained Earnings (Balance) -27.2m / Total Assets 1.24b

(D) -0.26 = Book Value of Equity -26.1m / Total Liabilities 102.2m

Total Rating: 5.07 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 88.50

1. Piotroski 4.50pt

2. FCF Yield 2.58%

3. FCF Margin 44.37%

4. Debt/Equity 0.01

5. Debt/Ebitda -2.24

6. ROIC - WACC (= 30.56)%

7. RoE 19.36%

8. Rev. Trend 91.54%

9. EPS Trend 84.62%

What is the price of KRYS shares?

As of January 07, 2026, the stock is trading at USD 249.39 with a total of 395,137 shares traded.
Over the past week, the price has changed by +0.61%, over one month by +6.55%, over three months by +38.11% and over the past year by +60.06%.

Is KRYS a buy, sell or hold?

Krystal Biotech has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy KRYS.

Strong Buy: 8
Buy: 2
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the KRYS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	231.6	-7.1%
Analysts Target Price	231.6	-7.1%
ValueRay Target Price	351.8	41.1%

KRYS Fundamental Data Overview January 03, 2026

Market Cap USD = 7.15b (7.15b USD * 1.0 USD.USD)
P/E Trailing = 36.9072
P/E Forward = 33.2226
P/S = 19.1579
P/B = 6.2828
Beta = 0.483
Revenue TTM = 373.2m USD
EBIT TTM = 164.8m USD
EBITDA TTM = 171.2m USD
Long Term Debt = 9.51m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.70m USD (from shortTermDebt, last quarter)
Debt = 9.51m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -383.1m USD (from netDebt column, last quarter)
Enterprise Value = 6.43b USD (7.15b + Debt 9.51m - CCE 731.1m)
Interest Coverage Ratio = -7.45 (Ebit TTM 164.8m / Interest Expense TTM -22.1m)
FCF Yield = 2.58% (FCF TTM 165.6m / Enterprise Value 6.43b)
FCF Margin = 44.37% (FCF TTM 165.6m / Revenue TTM 373.2m)
Net Margin = 53.30% (Net Income TTM 198.9m / Revenue TTM 373.2m)
Gross Margin = 93.89% ((Revenue TTM 373.2m - Cost of Revenue TTM 22.8m) / Revenue TTM)
Gross Margin QoQ = 94.21% (prev 92.54%)
Tobins Q-Ratio = 5.18 (Enterprise Value 6.43b / Total Assets 1.24b)
Interest Expense / Debt = 262.9% (Interest Expense 25.0m / Debt 9.51m)
Taxrate = -65.46% (out of range, set to none) (-31.4m / 48.0m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 10.14 (Total Current Assets 925.6m / Total Current Liabilities 91.3m)
Debt / Equity = 0.01 (Debt 9.51m / totalStockholderEquity, last quarter 1.14b)
Debt / EBITDA = -2.24 (Net Debt -383.1m / EBITDA 171.2m)
Debt / FCF = -2.31 (Net Debt -383.1m / FCF TTM 165.6m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.04% (Net Income 198.9m / Total Assets 1.24b)
RoE = 19.36% (Net Income TTM 198.9m / Total Stockholder Equity 1.03b)
RoCE = 15.90% (EBIT 164.8m / Capital Employed (Equity 1.03b + L.T.Debt 9.51m))
RoIC = 39.46% (EBIT 164.8m / (Assets 1.24b - Curr.Liab 91.3m - Cash 731.1m))
WACC = 8.90% (E(7.15b)/V(7.16b) * Re(8.91%) + (debt cost/tax rate unavailable))
Discount Rate = 8.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.75%
[DCF Debug] Terminal Value 66.63% ; FCFE base≈122.6m ; Y1≈80.5m ; Y5≈36.8m
Fair Price DCF = 21.66 (DCF Value 628.2m / Shares Outstanding 29.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 84.62 | EPS CAGR: 22.19% | SUE: -2.47 | # QB: 0
Revenue Correlation: 91.54 | Revenue CAGR: 166.7% | SUE: 0.68 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.52 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=8.30 | Chg30d=-0.006 | Revisions Net=-1 | Growth EPS=+27.0% | Growth Revenue=+44.6%

Additional Sources for KRYS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle